Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Nivolumab Colorectal Cancer	Fred Hutchinson Cancer Center	P3	BBB (74)
Nivolumab Metastatic Malignant Neoplasm	Fred Hutchinson Cancer Center	P3	BBB (74)
Nivolumab Plasma Cell Myeloma	Wake Forest University Health Sciences	P3	BBB (74)
Nivolumab Prostate Cancer	Exelixis	P3	BBB (74)
Nivolumab Skin Cancer	7 Hills Pharma, LLC	P3	BBB (74)
Nivolumab Urothelial Carcinoma	Fred Hutchinson Cancer Center	P3	BBB (74)
Nogitecan Ovarian Cancer	Genmab	P3	BBB (74)
Obinutuzumab B-Cell Chronic Lymphocytic Leukemia	Paolo Caimi, MD	P3	BBB (74)
Obinutuzumab Diffuse Large B-Cell Lymphoma	National Cancer Institute (NCI)	P3	BBB (74)
Obinutuzumab Lymphoma	Brown University	P3	BBB (74)
Obinutuzumab Marginal Zone Lymphoma	Ruijin Hospital	P3	BBB (74)
Oxaliplatin Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P3	BBB (74)
Oxaliplatin Colorectal Adenocarcinoma	Pfizer	P3	BBB (74)
Oxaliplatin Esophageal Adenocarcinoma	I-Mab Biopharma US Limited	P3	BBB (74)
Oxaliplatin Follicular Lymphoma	Yazeed Sawalha	P3	BBB (74)
Oxaliplatin Lymphoma	Brown University	P3	BBB (74)
Oxaliplatin Ovarian Cancer	Qilu Pharmaceutical Co., Ltd.	P3	BBB (74)
Oxaliplatin Ovarian Carcinoma	Moscow Regional Oncological Dispensary	P3	BBB (74)
Oxaliplatin Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P3	BBB (74)
Oxaliplatin Relapsed/Refractory Diffuse Large B-Cell Lymphoma	City of Hope Medical Center	P3	BBB (74)
Oxaliplatin Neoplasm	Mirati Therapeutics Inc.	P3	BBB (74)
Oxodotreotide Neuroendocrine Neoplasm	Fundación de investigación HM	P3	BBB (74)
Padeliporfin Prostate Cancer	Steba Biotech S.A.	P3	BBB (74)
Pembrolizumab Ovarian Cancer	Kalinski, Pawel, MD, PhD	P3	BBB (74)
Pembrolizumab Prostate Cancer	Icahn School of Medicine at Mount Sinai	P3	BBB (74)

Showing 1976 to 2000 of 42,289 assets

PreviousPage 80 of 1692Next